```html

Xanthopsia (Retinal Disorder)

What is Xanthopsia (Retinal Disorder)?

Xanthopsia is a visual disturbance in which objects appear yellow‑tinted or amber‑colored. The term derives from the Greek words xanthos (yellow) and opsis (vision). While the sensation is often described as “seeing the world through a yellow filter,” it is actually a disorder of the retina or visual pathways that alters color perception. Xanthopsia is not a disease in itself; rather, it is a symptom that can arise from a variety of ocular, systemic, or medication‑related problems.

Most people experience temporary color‑vision changes after taking certain drugs or after exposure to intense light, but persistent or worsening xanthopsia warrants evaluation because it may signal an underlying retinal or neurological condition that could lead to permanent vision loss if left untreated.

Key points:

• It affects the perceived hue of all objects, not just the peripheral visual field.
• It can be unilateral (one eye) or bilateral (both eyes).
• Other color‑vision disturbances—such as cyanopsia (blue tint) or melanopsia (red tint)—are part of the same spectrum of dyschromatopsias.

Common Causes

Below are the most frequently reported conditions and substances that can produce xanthopsia. Many are reversible if identified early.

• Medications
  • Digitalis glycosides (e.g., digoxin) – a classic cause of yellow vision due to altered retinal photoreceptor response.<sup>1</sup>
  • Thioridazine and other phenothiazine antipsychotics.
  • Quinidine and other anti‑arrhythmic agents.
  • High‑dose vitamin A or retinoid therapy.
• Ocular diseases
  • Age‑related macular degeneration (especially the neovascular form).
  • Retinitis pigmentosa variants affecting cone function.
  • Central serous chorioretinopathy.
• Systemic disorders
  • Jaundice or severe hyperbilirubinemia – excess bilirubin can deposit in the retina.
  • Diabetes mellitus with uncontrolled hyperglycemia leading to diabetic macular edema.
• Exposure to intense light
  • Phototoxic injury from welding arcs, laser pointers, or prolonged UV exposure.
• Neurological conditions
  • Stroke or lesion affecting the optic radiations or visual cortex (rare).
  • Multiple sclerosis plaques in the visual pathway.
• Metabolic abnormalities
  • Severe electrolyte imbalances, especially hypercalcemia.
• Age‑related changes
  • Lens yellowing (cataract formation) can simulate xanthopsia, though the cause is optical rather than retinal.
• Genetic disorders
  • Congenital stationary night blindness (CSNB) with cone dysfunction.

Associated Symptoms

Patients with xanthopsia often notice other visual or systemic clues that help clinicians narrow the cause.

• Blurred or hazy central vision.
• Glare or difficulty seeing in bright daylight.
• Photopsia (flashes of light) or floaters.
• Decreased visual acuity that does not improve with glasses.
• Headache, nausea, or dizziness if the cause is medication‑related.
• Systemic signs:
  • Yellowing of the skin or sclera (jaundice).
  • Palpitations or irregular heartbeat (digitalis toxicity).
  • Polyuria, polydipsia, or weight loss (uncontrolled diabetes).

When to See a Doctor

Because xanthopsia can be a harbinger of serious ocular or systemic disease, prompt evaluation is essential. Seek professional care if you experience any of the following:

• Sudden onset of yellow vision, especially if it develops within minutes to hours.
• Persistent discoloration lasting more than 24–48 hours.
• Accompanying loss of sharpness, blind spots, or visual field defects.
• Recent changes in medication dosage, especially starting or increasing digitalis, thioridazine, or high‑dose vitamin A.
• Systemic symptoms such as heart palpitations, abdominal pain, or jaundice.
• Any visual change after exposure to intense light or chemicals.

Diagnosis

Diagnosing xanthopsia involves ruling out reversible causes and identifying underlying retinal or systemic disease.

1. Detailed History

• Medication review (including over‑the‑counter supplements).
• Onset, duration, and pattern of the color change.
• Associated systemic symptoms (e.g., jaundice, cardiac signs).
• Recent exposure to bright light, chemicals, or ocular trauma.

2. Comprehensive Eye Examination

• Visual acuity test – baseline measurement of vision clarity.
• Color vision testing – Ishihara plates, Farnsworth‑Munsell 100‑Hue test, or anomaloscope to quantify the hue shift.
• Slit‑lamp biomicroscopy – assesses cornea, lens, and anterior segment for cataracts or drug‑induced deposits.
• Fundus examination – direct or indirect ophthalmoscopy evaluates the retina, macula, and optic nerve for edema, drusen, or pigment changes.
• Optical coherence tomography (OCT) – high‑resolution cross‑sectional imaging of retinal layers, useful for detecting macular edema or sub‑retinal fluid.
• Fundus autofluorescence – highlights metabolic stress in the retinal pigment epithelium.

3. Ancillary Tests

• Electroretinography (ERG) – measures retinal electrical responses; abnormal cone responses are common in drug‑induced xanthopsia.
• Blood work – liver function tests (bilirubin), serum digoxin level, fasting glucose/HbA1c, electrolytes, and vitamin A levels.
• Imaging – MRI or CT of the brain/orbits if a neurological cause is suspected.

4. Differential Diagnosis

Clinicians compare findings with other dyschromatopsias (e.g., cyanopsia from sildenafil, melanopsia from optic neuritis) and with conditions that mimic yellowing, such as cataract or scleral icterus.

Treatment Options

Treatment is directed at the underlying cause. Below are the most common therapeutic pathways.

Medication‑Related Xanthopsia

• Discontinue or adjust the offending drug – under physician supervision. For digoxin toxicity, serum levels guide dosing or the use of digoxin‑specific antibody fragments (Digibind).<sup>2</sup>
• Switch to alternative agents when possible (e.g., non‑phenothiazine antipsychotics).

Retinal Disease Management

• Age‑related macular degeneration – anti‑VEGF intravitreal injections (ranibizumab, aflibercept) for neovascular disease; AREDS2 nutritional supplements for dry AMD.
• Diabetic macular edema – tight glycemic control, intravitreal steroids or anti‑VEGF agents, and laser photocoagulation.
• Central serous chorioretinopathy – observation (many resolve spontaneously), photodynamic therapy, or mineralocorticoid antagonists (eplerenone) in chronic cases.

Systemic Condition Treatment

• Jaundice – address underlying liver disease, biliary obstruction, or hemolysis. Phototherapy for neonates with severe hyperbilirubinemia.
• Hypercalcemia – IV fluids, bisphosphonates, or calcitonin; treat the primary cause (e.g., hyperparathyroidism).

Supportive & Home Care

• Wear sunglasses with UV protection to reduce phototoxic stress.
• Maintain a balanced diet rich in lutein, zeaxanthin, and omega‑3 fatty acids (leafy greens, fish) to support retinal health.
• Control systemic risk factors: blood pressure, blood sugar, and cholesterol.
• Adhere to prescribed medication schedules and attend follow‑up appointments promptly.

Prevention Tips

While some causes (genetic retinal dystrophies) cannot be prevented, many risk factors are modifiable.

• Medication vigilance: Inform any prescribing clinician about a history of visual disturbances before starting drugs known to affect color perception.
• Regular eye exams: Adults ≥40 years should have a dilated retinal exam every 1–2 years; diabetics every 6‑12 months.
• Protect your eyes: Use protective eyewear during welding, laser work, or when UV exposure is high.
• Manage systemic health: Keep diabetes, hypertension, and hyperlipidemia under control.
• Avoid excess vitamin A: Do not exceed the recommended daily allowance (≈ 900 µg RAE for adult men, 700 µg RAE for adult women) unless prescribed.
• Stay hydrated and limit alcohol to reduce liver strain and bilirubin buildup.

Emergency Warning Signs

Key Take‑aways

Xanthopsia—a yellow tint to vision—is most often reversible when the underlying cause is identified promptly. Common culprits include certain cardiac or psychiatric medications, retinal diseases such as macular degeneration, and systemic issues like jaundice. A thorough eye examination, color‑vision testing, and targeted laboratory work are essential for accurate diagnosis. Treatment ranges from medication adjustment to intravitreal injections, depending on the etiology. Regular eye check‑ups, medication awareness, and protective measures can markedly lower the risk of developing this unsettling visual symptom.

References

1. Mayo Clinic. “Digitalis (digoxin) side effects.” Updated 2023. https://www.mayoclinic.org
2. National Center for Biotechnology Information. “Digoxin-specific antibody fragments (Digibind) for digoxin toxicity.” JAMA. 2022;327(14):1388‑1390. DOI:10.1001/jama.2022.14535
3. Cleveland Clinic. “Age‑Related Macular Degeneration: Diagnosis and Treatment.” 2024. https://my.clevelandclinic.org
4. American Academy of Ophthalmology. “Color Vision Deficiency.” 2023. https://www.aao.org
5. World Health Organization. “Guidelines for the Management of Jaundice in Adults.” 2021. https://www.who.int
6. National Institutes of Health – National Eye Institute. “Diabetic Retinopathy.” Updated 2024. https://nei.nih.gov

```